Refine by
Cancer Genomics Articles & Analysis
76 news found
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was ...
MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of the highly validated liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution. The solution combines the sophisticated analytics, state-of-the-art algorithms, and decentralized, cloud-based offerings of the SOPHiA ...
This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. The ELBS primarily focuses on liquid biopsy ...
CD Genomics, a pioneering leader in genomic solutions, is proud to announce its cutting-edge whole genome sequencing (WGS) services. ...
Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, aims to enhance cell culture results by providing researchers and laboratories with a variety of simple and high-performance 3D cell culture systems. Three-dimensional (3D) cell culture provides an artificially created microenvironment to achieve optimal cell growth, ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. ...
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. As a leader in the sector, it’s important to be aware of these developments to make informed decisions about your organization’s direction. In this blog post, we’ll explore some of the most significant emerging trends in ...
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early 2024. The company previously ...
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle ...
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement. This agreement covers the execution of a Phase 2 clinical trial to evaluate the novel combination of ...
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients An exploratory analysis of biomarkers from the MANIFEST trial indicates the potential for disease modification MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ...
Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients’ diagnostics. This is achieved by developing and providing integrated and standardized workflows for Next Generation Sequencing (NGS) and integrating information from cancer gene testing, pharmacogenetics testing and e-medication, to support medical ...
CD Genomics is a world-leading genomics services company that continues to innovate in sequencing solutions for the genomics industry, covering genotyping, library construction, bioinformatics, microarrays, mutagenesis analysis, and more. ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. DR NADINE COLLINS, CONSULTANT CLINICAL SCIENTIST IN MOLECULAR DIAGNOSTICS WHO IS BASED AT ...
Vividion has options to pursue up to five additional targets with up to $482 million in potential additional future payments. “The future of cancer treatment lies in the precision targeting of therapies in the optimal clinical settings. ...
ByBayer AG
A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ANNOUNCED THE OFFICIAL ...